Insider Selling: DexCom (NASDAQ:DXCM) EVP Sells 1,700 Shares of Company Stock

DexCom, Inc. (NASDAQ:DXCM) EVP Michael Brown sold 1,700 shares of the business’s stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $85.48, for a total transaction of $145,316.00. Following the completion of the transaction, the executive vice president directly owned 98,185 shares of the company’s stock, valued at $8,392,853.80. This trade represents a 1.70% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Michael Jon Brown also recently made the following trade(s):

• On Tuesday, September 15th, Michael Brown sold 1,700 shares of DexCom stock. The shares were sold at an average price of $84.04, for a total value of $142,868.00.

DexCom Stock Down 0.1%

DexCom stock traded down $0.06 during trading hours on Monday, reaching $85.98. The stock had a trading volume of 2,590,456 shares, compared to its average volume of 4,972,389. The company has a market cap of $32.45 billion, a price-to-earnings ratio of 33.98, a PEG ratio of 1.44 and a beta of 1.48. The business’s 50 day moving average price is $87.61 and its 200-day moving average price is $75.96. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $92.59. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.73 and a quick ratio of 1.43.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, July 30th. The medical device company reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.61 by $0.09. DexCom had a return on equity of 35.94% and a net margin of 20.12%. The firm had revenue of $1.31 billion during the quarter, compared to analysts’ expectations of $1.29 billion. During the same quarter last year, the firm earned $0.48 EPS. The business’s quarterly revenue was up 13.1% on a year-over-year basis. Sell-side analysts anticipate that DexCom, Inc. will post 2.64 EPS for the current year.

Institutional Investors Weigh In On DexCom

Large investors have recently bought and sold shares of the company. BDF Gestion purchased a new position in DexCom during the third quarter worth approximately $1,630,000. USA Financial Formulas acquired a new position in DexCom during the third quarter worth $747,000. TD Waterhouse Canada Inc. grew its holdings in DexCom by 17.4% in the 3rd quarter. TD Waterhouse Canada Inc. now owns 7,873 shares of the medical device company’s stock valued at $680,000 after buying an additional 1,169 shares in the last quarter. V Square Quantitative Management LLC grew its holdings in DexCom by 8.6% in the 3rd quarter. V Square Quantitative Management LLC now owns 4,301 shares of the medical device company’s stock valued at $371,000 after buying an additional 339 shares in the last quarter. Finally, Curated Wealth Partners LLC purchased a new stake in DexCom in the 3rd quarter valued at $333,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. Weiss Ratings upgraded shares of DexCom from a “hold (c)” rating to a “hold (c+)” rating in a report on Tuesday, October 6th. UBS Group set a $96.00 price objective on shares of DexCom and gave the company a “buy” rating in a research report on Tuesday, July 28th. BTIG Research lifted their target price on shares of DexCom from $90.00 to $96.00 and gave the stock a “buy” rating in a research note on Monday, October 12th. Raymond James Financial reissued a “strong-buy” rating and set a $94.00 target price on shares of DexCom in a research report on Friday, July 31st. Finally, Barclays upgraded shares of DexCom to a “strong-buy” rating in a research note on Wednesday, October 7th. Three analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, DexCom presently has a consensus rating of “Buy” and a consensus target price of $92.43.

DexCom Company Profile

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its devices use a small wearable sensor to measure glucose levels in real time and transmit readings to compatible smartphones, receivers, smartwatches, and other connected devices, helping users monitor glucose trends and make informed decisions about their health.

The company’s product portfolio includes the Dexcom G7 and Dexcom G6 CGM systems, as well as Dexcom ONE and Dexcom ONE+ products offered in select markets.